SKY92-ISS Superior to current markers in risk classification for myeloma survival

Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients

Rotterdam, the Netherlands, 8 September 2015 – Researchers at the Erasmus Medical Center in Rotterdam, the Netherlands, conclude that the SKY92-signature (formerly known as EMC92) for genetic subtyping of multiple myeloma patients in combination with the ISS (the International Staging System) classification is superior to all other markers in risk classification for survival. Their findings have been published in the well-known international haematological journal, Blood.

Patients with multiple myeloma (bone marrow cancer) have variable survival, and require reliable prognostic and predictive scoring systems.

The SKY92-signature, discovered by the Erasmus Medical Centre in the Netherlands, consists of 92 genes that are directly or indirectly related to the disease, the combined expression level of these genes can be measured using the MMprofiler. Clinicians can use the result of the MMprofiler test to predict for their patients how multiple myeloma is likely to progress and to decide on the most optimal treatment for the individual patient.

According to the article in Blood, the SKY92-signature in combination with the ISS (international staging system) classification, outperforms current markers and offers a robust clinically relevant 4-group model: “Ranking all novel as well as existing risk classifications showed that the EMC92(SKY92)-ISS combination is the strongest predictor for overall survival, resulting in a four group risk classification. The median survival was 24 months for the highest risk group, 47 and 61 months for the intermediate risk groups and the median was not reached after 96 months for the lowest risk group”, the researchers from the Erasmus Medical Center noted.

The SKY92-signature is used by SkylineDx in its leading diagnostic test, the MMprofiler. On July 3rd 2015 SkylineDx launched its MMprofiler as a Diagnostic Service in the Netherlands and the rest of Europe, making it possible for physicians to send their samples to the SkylineDx central laboratory in Rotterdam for analysis with the MMprofiler. SkylineDx expects to launch the MMprofiler as a CE IVD kit on the European market later this year. This will enable other molecular diagnostics laboratories throughout Europe to implement the MMprofiler for analysis at their own facility.

About SkylineDx
SkylineDx is a Rotterdam-based biotech company. SkylineDx is a spin-off of the Erasmus Medical Center in Rotterdam, the Netherlands. The company specializes in the development and marketing of innovative gene signature-based diagnostic tests based with high clinical value to enable healthcare professionals to make better informed treatment decisions for individual patients.
The MMprofiler is the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.

About Multiple Myeloma
www.hematon.nl/myeloom *(information available in Dutch only)*
http://www.myeloma.org.uk/information/what-is-myeloma/

About the MMprofiler
In the USA available for research use only and currently not permitted to be used for clinical diagnostic use.

www.mmprofiler.com

Contacts

**SkylineDx B.V.**
Dharminder S. Chahal, CEO
Rotterdam Science Tower
Marconistraat 16
3029 AK Rotterdam,
The Netherlands
+31 (0)10 7038410
d.chahal@skylinedx.com

**SPJ Financiële en Corporate Communicatie**
Léon Melens, Maaike Noordhuis
lmelens@spj.nl, mnoordhuis@spj.nl
+31 (0)20 647 81 81